 |
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Previous Article | Next Article
The Journal of Neuroscience, July 1, 2002, 22(13):5669-5678
Chronic But Not Acute Treatment with a Metabotropic Glutamate 5 Receptor Antagonist Reverses the Akinetic Deficits in a Rat Model of Parkinsonism
Nathalie Breysse1, Christelle Baunez1, Will Spooren2, Fabrizio Gasparini2, and Marianne Amalric1 1 Laboratoire de Neurobiologie Cellulaire et Fonctionnelle, Centre National de la Recherche Scientifique, 13402 Marseille cedex 20, France, and 2 Novartis Pharma AG, Basel CH-4002, Switzerland
Metabotropic glutamate receptors (mGluRs) have recently been considered as potential pharmacological targets in the treatment of neurodegenerative disorders and particularly in parkinsonism. Within the basal ganglia, receptors of group I (mGluR1 and mGluR5) are widely expressed; the present study was thus aimed at blocking these receptors in a 6-hydroxydopamine (6-OHDA) model of Parkinson's disease in the rat. Considering the prominent expression of mGluR5, we have used the selective mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) to target these receptors. In rats trained to quickly depress a lever after a visual cue, bilateral lesions of the dopaminergic nerve terminals in the striatum produced severe akinetic deficits, which were expressed by increases in delayed responses and reaction times. Acute MPEP injection (1.5, 3, and 6 mg/kg, i.p.) had no effect, whereas chronic administration, ineffective in a control group, significantly reversed the akinetic deficits. Alleviation of these deficits was seen after 1 week of treatment, and the preoperative performance was fully recovered after a 3 week treatment of MPEP at all doses. Chronic MPEP also induced ipsilateral rotation in the unilateral 6-OHDA circling model. However, no effect was seen of MPEP (1.5, 3, or 6 mg/kg, i.p.) on haloperidol-induced catalepsy (1 mg/kg, i.p.). Altogether, these results suggest a specific role of mGluRs in the regulation of extrapyramidal motor functions and a potential therapeutic value for mGluR5 antagonists in the treatment of Parkinson's disease.
Key words: basal ganglia; metabotropic receptor antagonist; 6-OHDA lesions; Parkinson's disease; reaction time task; glutamate; metabotropic receptors (mGluR5 subtype); MPEP; rat
Copyright © 2002 Society for Neuroscience 0270-6474/02/22135669-10$05.00/0
This article has been cited by other articles:
S. Lopez, N. Turle-Lorenzo, F. Acher, E. De Leonibus, A. Mele, and M. Amalric
Targeting Group III Metabotropic Glutamate Receptors Produces Complex Behavioral Effects in Rodent Models of Parkinson's Disease
J. Neurosci., June 20, 2007; 27(25): 6701 - 6711.
[Abstract] [Full Text] [PDF]
M. Kuwajima, M. H. Dehoff, T. Furuichi, P. F. Worley, R. A. Hall, and Y. Smith
Localization and Expression of Group I Metabotropic Glutamate Receptors in the Mouse Striatum, Globus Pallidus, and Subthalamic Nucleus: Regulatory Effects of MPTP Treatment and Constitutive Homer Deletion
J. Neurosci., June 6, 2007; 27(23): 6249 - 6260.
[Abstract] [Full Text] [PDF]
G. Battaglia, C. L. Busceti, G. Molinaro, F. Biagioni, A. Traficante, F. Nicoletti, and V. Bruno
Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
J. Neurosci., July 5, 2006; 26(27): 7222 - 7229.
[Abstract] [Full Text] [PDF]
A. Kachroo, L. R. Orlando, D. K. Grandy, J.-F. Chen, A. B. Young, and M. A. Schwarzschild
Interactions between Metabotropic Glutamate 5 and Adenosine A2A Receptors in Normal and Parkinsonian Mice
J. Neurosci., November 9, 2005; 25(45): 10414 - 10419.
[Abstract] [Full Text] [PDF]
R. H. P. Porter, G. Jaeschke, W. Spooren, T. M. Ballard, B. Buttelmann, S. Kolczewski, J.-U. Peters, E. Prinssen, J. Wichmann, E. Vieira, et al.
Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity
J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 711 - 721.
[Abstract] [Full Text] [PDF]
B. A. McMILLEN, M. S. CRAWFORD, C. M. KULERS, and H. L. WILLIAMS
EFFECTS OF A METABOTROPIC, MGLU5, GLUTAMATE RECEPTOR ANTAGONIST ON ETHANOL CONSUMPTION BY GENETIC DRINKING RATS
Alcohol Alcohol., November 1, 2005; 40(6): 494 - 497.
[Abstract] [Full Text] [PDF]
E. De Leonibus, A. Oliverio, and A. Mele
A study on the role of the dorsal striatum and the nucleus accumbens in allocentric and egocentric spatial memory consolidation
Learn. Mem., September 1, 2005; 12(5): 491 - 503.
[Abstract] [Full Text] [PDF]
K. Naie and D. Manahan-Vaughan
Regulation by Metabotropic Glutamate Receptor 5 of LTP in the Dentate Gyrus of Freely Moving Rats: Relevance for Learning and Memory Formation
Cereb Cortex, February 1, 2004; 14(2): 189 - 198.
[Abstract] [Full Text] [PDF]
G. Battaglia, C. L. Busceti, G. Molinaro, F. Biagioni, M. Storto, F. Fornai, F. Nicoletti, and V. Bruno
Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice
J. Neurosci., January 28, 2004; 24(4): 828 - 835.
[Abstract] [Full Text] [PDF]
K. Fuxe, L.F. Agnati, K. Jacobsen, J. Hillion, M. Canals, M. Torvinen, B. Tinner-Staines, W. Staines, D. Rosin, A. Terasmaa, et al.
Receptor heteromerization in adenosine A2A receptor signaling: Relevance for striatal function and Parkinson's disease
Neurology, December 9, 2003; 61(90116): S19 - 23.
[Abstract] [Full Text]
K.-Z. Shen and S. W Johnson
Group II metabotropic glutamate receptor modulation of excitatory transmission in rat subthalamic nucleus
J. Physiol., December 1, 2003; 553(2): 489 - 496.
[Abstract] [Full Text] [PDF]
M. J. Marino, D. L. Williams Jr., J. A. O'Brien, O. Valenti, T. P. McDonald, M. K. Clements, R. Wang, A. G. DiLella, J. F. Hess, G. G. Kinney, et al.
Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment
PNAS, November 11, 2003; 100(23): 13668 - 13673.
[Abstract] [Full Text] [PDF]
P. Malherbe, N. Kratochwil, M.-T. Zenner, J. Piussi, C. Diener, C. Kratzeisen, C. Fischer, and R. H. P. Porter
Mutational Analysis and Molecular Modeling of the Binding Pocket of the Metabotropic Glutamate 5 Receptor Negative Modulator 2-Methyl-6-(phenylethynyl)-pyridine
Mol. Pharmacol., October 1, 2003; 64(4): 823 - 832.
[Abstract] [Full Text] [PDF]
N. Breysse, M. Amalric, and P. Salin
Metabotropic Glutamate 5 Receptor Blockade Alleviates Akinesia by Normalizing Activity of Selective Basal-Ganglia Structures in Parkinsonian Rats
J. Neurosci., September 10, 2003; 23(23): 8302 - 8309.
[Abstract] [Full Text] [PDF]
L. F. Agnati, S. Ferre, C. Lluis, R. Franco, and K. Fuxe
Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons
Pharmacol. Rev., September 1, 2003; 55(3): 509 - 550.
[Abstract] [Full Text] [PDF]
O. V. Poisik, G. Mannaioni, S. Traynelis, Y. Smith, and P. J. Conn
Distinct Functional Roles of the Metabotropic Glutamate Receptors 1 and 5 in the Rat Globus Pallidus
J. Neurosci., January 1, 2003; 23(1): 122 - 130.
[Abstract] [Full Text] [PDF]
|
|
|
|
 |
|